DCM
RNTX

DAFNA Capital Management’s Rein Therapeutics RNTX Stock Holding History

DAFNA Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-22,500
Closed -$531K – 89
2020
Q2 		$531K Buy
+22,500
New +$367K 0.15% 76
2019
Q4 		– Sell
-4,975
Closed -$67K – 87
2019
Q3 		$67K Hold
4,975
– – 0.03% 88
2019
Q2 		$72K Hold
4,975
– – 0.03% 84
2019
Q1 		$194K Buy
+4,975
New +$155K 0.08% 75

Other funds holding RNTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

DAFNA Capital Management's RNTX Position: Q3 2020 in Review

DAFNA Capital Management sold out of Rein Therapeutics (RNTX) in Q3 2020, closing a stake of 22,500 shares — an estimated $531K sold.

DAFNA Capital Management first reported a position in RNTX in Q1 2019 and held it in 4 quarters. The position peaked at $531K in Q2 2020. 28 funds tracked by Wall St. Rank hold RNTX as of Q3 2020.

  • DAFNA Capital Management reported no remaining Rein Therapeutics position as of Q3 2020 after selling out during the quarter.
  • DAFNA Capital Management sold 22,500 Rein Therapeutics shares in Q3 2020, an estimated $531K.
  • DAFNA Capital Management first reported a position in Rein Therapeutics in Q1 2019 and held it in 4 quarters.
  • DAFNA Capital Management's Rein Therapeutics position peaked at $531K in Q2 2020.
  • 28 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2020.

Based on DAFNA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.